Hence, it is crucial to adopt at least dual BCL-2/BCL-xL BH3-mimetic (ABT-263), or even pan-BCL-2 family BH3-mimetic (obatoclax) inhibitor [20, 24, 25, 35–37], in order to effectively prevent or eradicate early adaptive mitochondrially-primed tumor escape. This evidence concerns the gene BCL2 and neoplasm.